Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Abstract

The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the subject invention provides methods for treating or controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V. In another embodiment, the subject invention provides for methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V. Compositions may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury. The invention also provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V.

1 . A method of treating dermatological injury or tissue damage comprising: 
 a) providing an individual having a dermatological injury or tissue damage; and    b) administering, to said individual, a therapeutically effective amount of a composition comprising a carrier and an anticonvulsant agent of the formula:                          wherein    X 1  is CH 2  or oxygen;    R 1  is hydrogen or alkyl; and    R 2 , R 3 , R 4 , and R 5  are independently hydrogen or lower alkyl and, when X 1  is CH 2 , R 4  and R 5  can combine to form a benzene ring and when X 1  is oxygen, R 2  and R 3  and/or R 4  and R 5  together may be a methylenedioxy group of the following formula:                          wherein R 6  and R 7  are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.    
     
     
         2 . The method according to  claim 1 , wherein said composition is topically administered, orally administered, parenterally administered or administered via injection.  
     
     
         3 . The method according to  claim 1 , wherein said composition comprises a salve, ointment, aerosol, cosmetic, liquid, tablet, powder, capsule, or bioadhesive.  
     
     
         4 . The method according to  claim 1 , wherein said composition is administered as a component of a bandage, transdermal patch, wound dressing, cosmetic, or bioadhesive.  
     
     
         5 . The method according to  claim 2 , wherein said composition is topically administered.  
     
     
         6 . The method according to  claim 2 , wherein said composition is orally administered.  
     
     
         7 . The method according to  claim 2 , wherein said composition is parenterally administered.  
     
     
         8 . The method according to  claim 2 , wherein said composition is administered via injection.  
     
     
         9 . The method according to  claim 1 , wherein the anticonvulsant agent of Formula I is topiramate (2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate).  
     
     
         10 . The method according to  claim 9 , wherein the dosage of topiramate is: a) 0.1 mg to about 400 mg; b) about 10 mg to about 200 mg; c) about 20 mg to about 100 mg; or d) about 25 mg.  
     
     
         11 . A method of promoting wound healing comprising: 
 a) providing an individual having a wound; and    b) administering, to said individual, a therapeutically effective amount of a composition comprising a carrier and an anticonvulsant agent of the formula:                          wherein    X 1  is CH 2  or oxygen;    R 1  is hydrogen or alkyl; and    R 2 , R 3 , R 4 , and R 5  are independently hydrogen or lower alkyl and, when X 1  is CH 2 , R 4  and R 5  can combine to form a benzene ring and when X 1  is oxygen, R 2  and R 3  and/or R 4  and R 5  together may be a methylenedioxy group of the following formula:                          wherein R 6  and R 7  are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.    
     
     
         12 . The method according to  claim 11 , wherein said composition is topically administered, orally administered, parenterally administered or administered via injection.  
     
     
         13 . The method according to  claim 11 , wherein said composition comprises a salve, ointment, aerosol, cosmetic, liquid, tablet, powder, capsule, or bioadhesive.  
     
     
         14 . The method according to  claim 11 , wherein said composition is administered as a component of a bandage, transdermal patch, wound dressing, cosmetic, or bioadhesive.  
     
     
         15 . The method according to  claim 12 , wherein said composition is topically administered.  
     
     
         16 . The method according to  claim 11 , wherein the anticonvulsant agent of Formula I is topiramate (2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate).  
     
     
         17 . The method according to  claim 16 , wherein the dosage of topiramate is: a) 0.1 mg to about 400 mg; b) about 10 mg to about 200 mg; c) about 20 mg to about 100 mg; or d) about 25 mg.  
     
     
         18 . A method for treating or controlling neurogenetic disorders in an individual comprising the administration of a therapeutically effective amount of a composition comprising an anti-convulsant agent and a pharmaceutically acceptable carrier; 
 wherein said neurogenetic disorders are selected from the group consisting of hereditary ataxias and related disorders, Friedreich ataxia, ataxia telangiectasia, olivopontine cerebellar degeneration, Ramsay Hunt syndrome, abetalipoproteinemia, Machado-Joseph disease, familial spastic paraparesis, movement disorders, juvenile Huntington disease, dystonias, blepharospasm, spasmodic torticolis, tremor, myoclonus, Hallervorden-Spatz disease, phakomatoses, neurocutaneous syndromes, neurofibromatosis, tuberous sclerosis, Sturge-Weber, Von Hippel-Landau disease, mitochondrial encephalomyopathies, MELAS syndrome, Keams-Sayre, Leigh disease, hereditary disorders of nerve and muscle, infantile spinal muscular atrophy, Charcot-Marie-Tooth disease, hereditary sensory and autonomic neuropathies, genetic myasthenic syndromes, metabolic myopathies, muscular dystrophies, myotonias, Laurence-Moon-Bardet-Biedl syndrome, Aicardi, Sjogren-Larsson syndrome, Prader-Willi syndrome, Angelman syndrome, gouging, oppositional behavior, and obsessive ruminations.    
     
     
         19 . The method according to  claim 18 , wherein said neurogenetic disorder is obsessive ruminations.  
     
     
         20 . The method according to  claim 18 , wherein said anticonvulsant agent has the formula:  
       
         
           
           
               
               
           
         
       
       wherein 
 X 1  is CH 2  or oxygen;  
 R 1  is hydrogen or alkyl; and  
 R 2 , R 3 , R 4 , and R 5  are independently hydrogen or lower alkyl and, when X 1  is CH 2 , R 4  and R 5  can combine to form a benzene ring and when X 1  is oxygen, R 2  and R 3  and/or R 4  and R 5  together may be a methylenedioxy group of the following formula:  
                     
 wherein R 6  and R 7  are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.